AltimmuneALT
ALT
About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Employees: 59
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
31% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $10.3M
2% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 52
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 180 [Q4 2024] → 173 (-7) [Q1 2025]
7.34% less ownership
Funds ownership: 56.87% [Q4 2024] → 49.53% (-7.34%) [Q1 2025]
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
35% less capital invested
Capital invested by funds: $292M [Q4 2024] → $191M (-$101M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
73%
upside
Avg. target
$18.50
167%
upside
High target
$25
261%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 73%upside $12 | Buy Reiterated | 3 Apr 2025 |
Citizens Capital Markets Jonathan Wolleben | 261%upside $25 | Market Outperform Reiterated | 2 Apr 2025 |
Financial journalist opinion
Based on 4 articles about ALT published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions
GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association's (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025.
Positive
Seeking Alpha
1 week ago
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks clear differentiation, despite financial stability.
Positive
Seeking Alpha
2 weeks ago
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, although pemvidutide will be compared to other competitors. ALT has also initiated a trial of pemvidutide in alcohol use disorder, with a trial in alcohol liver disease set to start in Q3'25.
Neutral
GlobeNewsWire
3 weeks ago
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
Neutral
Seeking Alpha
1 month ago
Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Roger Song - Jefferies Annabel Samimy - Stifel Mayank Mamtani - B Riley Andy Hsieh - William Blair Operator Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
Neutral
GlobeNewsWire
1 month ago
Altimmune Announces First Quarter 2025 Financial Results and Business Update
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md.
Neutral
GlobeNewsWire
1 month ago
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing.
Positive
Zacks Investment Research
1 month ago
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution
Charts implemented using Lightweight Charts™